Rafael(RFL) - 2025 Q2 - Quarterly Results

Financial Performance - Rafael Holdings reported a net loss of $4.6 million, or$0.19 per share, for the three months ended January 31, 2025, compared to a net income of $6.0 million, or$0.25 per share, in the same period last year [4]. - For the first six months of fiscal year 2025, the company recorded a net loss of $13.6 million, or$0.57 per share, versus a net income of $2.4 million, or$0.10 per share, in the prior year [7]. - Rafael Holdings experienced unrealized losses of $1.1 million on its investment in Cyclo equity during the quarter, compared to unrealized gains of$9.7 million in the prior year [4]. Cash and Assets - Cash and cash equivalents as of January 31, 2025, were $48.3 million, a significant increase from$2.7 million as of July 31, 2024 [3]. - The company reported a total equity of $69.4 million as of January 31, 2025, down from$82.2 million as of July 31, 2024 [13]. - The company’s total assets decreased to $83.0 million as of January 31, 2025, from$96.8 million as of July 31, 2024 [13]. Expenses - Research and development expenses for the three months ended January 31, 2025, were $0.9 million, up from$0.6 million in the same period last year [5]. - General and administrative expenses remained stable at $2.6 million for both the three months ended January 31, 2025, and 2024 [6]. Future Plans - The planned merger with Cyclo Therapeutics is expected to close in Q3 2025, pending shareholder approvals [1]. - The company anticipates topline data from the interim analysis of 104 enrolled patients in the Phase 3 trial for Trappsol Cyclo™ in mid-2025 [2].